President of CNCF. Member of the ACTION-Group. Associate Editor at Minerva Cardio-Angiology+Archives Med.Science-Scientific Director atAxis TV. tweets on my own
Very sad news today as my friend and great expert Pr Jean Philippe Collet let us suddenly. Great cardiologist and researcher, very kind with patients and team. I ´d rather keep him smiling. No words.
Ahead of print: "FOURIER to ODYSSEY: the end of the journey for lipid-lowering therapy trials? Lessons from recent clinical trials with anti-PCSK9 antibodies" by
@SABOURETCardio
, Denis Angoulvant and
@AtulPathak31
I just have reached the threshold of 10000 followers. Thanks to all, especially the first one.
#cardiotwitter
is a great source of knowledge, polite debates, new
#networking
Thanks to the amazing team of
#Philadelphia
to publish this useful
#MA
Metaanalysis on
#DAPT
. Third article on this topic with these « usual suspects ». Thanks also to all coauthors ☀️☀️
#HF
#cardiotwitter
: our practical expert guidance for
#diagnosis
and management of Heart Failure is online. Thanks to all coauthors especially
@ThibaudDamy
for this teamwork. Endorsed by the Working Group of HF of the French Society of Cardiology.
Do you speak
#lipids
?
#CLEAROutcomes
is online. A new validated option for
#Statins
intolerance. Obviously better in fixed combination with
#Ezetimibe
. Proven efficacy on
#MACE
. Expected and confirmed benefits according to magnitude of decrease/time exposure
Happy new year from
#Paris
. Stay strong, get vaccinated (if possible), and do your best ☀️. Many thanks to all followers for sharing knowledge and friendship.
#cardiotwitter
Guess who is the elected President of
@CNCFCardio
? In good company with Jean Claude Dib and Patrick Khanoyan the vice-presidents.
#WIC
are welcome ☀️
Last year, we published an article about
#LowLDL
and
#Safety
. New data reported during
#AHA23
by
@rgiugliano
‘s team reinforced two concepts: low LDL-c is safe (especially for
#ICH
and
#cognition
as the metabolism in the brain is specific) and also provides further benefits.
I am skeptical about the efficacy of
#statins
and other
#LLT
to reduce
#embolism
. They already reduce ischemic atherothrombotic
#stroke
but for
#AF
I remain doubtful
Glad to see that our article is now on
#pubmed
, available for Free. Thanks to all coauthors who provided their high value contribution.
#cardiotwitter
#CVR
I m wondering if “too many guidelines kill the guidelines “. For a GP, which GL are the more appropriate? In France : Nice, EASD, SFD, HAS, ADA ? In the end, therapeutic inertia and discrepancies with
#EBM
are observed in registries…
#T2D
#Cardiotwitter
Glad to see that our practical guide in
#HF
is downloaded by many colleagues. First to be published in July 21 before ESC congress. A team work by French experts.
Happy birthday to Adriana ☀️☀️. In US style : amazing wife, mother, teacher, writer, sister, art’s lover and friend.
@AdrianaSabouret
3 books accepted by Italian publishers. First available this summer, second in early 2022, third in summer 2022.
“Correlation is not causation “. Common risk factors such as smoking, diabetes, obesity, physical inactivity main explain this association. Useful article to keep in mind the association.
Dear
#cardiotwitter
friends, it’s my pleasure to announce my nomination as scientific director on AXIS-TV, the major French TV on CME. Many sessions will be in French and « even if you don’t understand French, it sounds good ». M. Gulati
@cardioPCImom
citations ☀️☀️
#ACS
#Guidelines
by
#CCS
. They consider that
#DAPT
De-escalation is a weak recommendation. The same for Ticagrelor or Prasugrel over Clopidogrel despite to old and well conducted
#RCT
#Suarez
last year was fired from
#Barca
because the President said he was too old for high level. Today he’s champion with
#Atletico
Madrid and best scorer with 21 goals.
#HF
pEF :
#SGLT2i
first line due to EMPEROR preserved. 2b for others due to the results of PARAGON (NS primary endpoint), TOPCAT (geographic differences), CHARM and I-PRESERVE (NS primary EP).
Long-term Safety and Efficacy of Achieving Very Low Levels of
#LDL
: A Prespecified Analysis of the IMPROVE-IT Trial. For those who underestimate CV benefits of
#ezetimibe
and of low
#LDL
#safety